SFI
SGMO

Susquehanna Fundamental Investments’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Susquehanna Fundamental Investments’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-69,267
Closed -$829K – 1870
2021
Q2 		$829K Buy
+69,267
New +$784K 0.02% 942

Other funds holding SGMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Susquehanna Fundamental Investments's SGMO Position: Q3 2021 in Review

Susquehanna Fundamental Investments sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2021, closing a stake of 69,267 shares — an estimated $829K sold.

Susquehanna Fundamental Investments first reported a position in SGMO in Q2 2021 and held it in 1 quarter. The position peaked at $829K in Q2 2021. 193 funds tracked by Wall St. Rank hold SGMO as of Q3 2021.

  • Susquehanna Fundamental Investments reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 69,267 SANGAMO THERAPEUTICS INC shares in Q3 2021, an estimated $829K.
  • Susquehanna Fundamental Investments first reported a position in SANGAMO THERAPEUTICS INC in Q2 2021 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's SANGAMO THERAPEUTICS INC position peaked at $829K in Q2 2021.
  • 193 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2021, filed 15 Nov 2021.